Mepolizumab Improves Eosinophilic Asthma Control, Study Shows

A recent study shows that interleukin 5 (IL-5) inhibition with mepolizumab seems to improve asthma control, cutting the incidences of exacerbations and hospitalizations, in patients with severe eosinophilic asthma treated in real-world setting.

Photo: 3D image of Human Lungs | InStyleHealth


Experts searched multiple online databases for real-world studies looking into severe asthma treatment with mepolizumab. Effectiveness was evaluated using indicators such as exacerbations, asthma-related hospitalizations, forced expiratory volume in 1 second (FEV1), Asthma Control Questionnaire (ACQ) or Asthma Control Test (ACT), corticosteroid use, peripheral blood eosinophil counts, and the fraction of exhaled nitric oxide.

The estimates for effect size were obtained using the Cohen method, with d values of 0.2, 0.5, and 0.8 indicating, small, medium, and large effects, correspondingly. The Dersimonian-Laird random-effect model was utilized to quantify pooled effectiveness estimations.

Analysis covered 13 cohorts with a total of 1,457 patients. With all time points, mepolizumab cut the incidences of exacerbations and hospitalizations. Treatment also generated improvements in asthma control and pulmonary function.

Oral corticosteroid usage requirement had decreased by 9.02 mg at 6 months and by 7.68 mg at 12 months. Peripheral blood eosinophil counts dropped by 559.11 cells/ μL at 1-3 months and by 599.17 cells/ μL at 6-12 months. Lastly, there was also a decrease of 13-ppb in fraction of exhaled nitric oxide at 6-12 months.

According to researchers that the findings serve as a supplement to and extension of the efficacy of randomized controlled trials of mepolizumab.

 

Source: Clin Ther 2021;doi:10.1016/j.clinthera.2021.03.023

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post